- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00462631
Paclitaxel Eluting Balloon Versus Drug Eluting Stent in Native Coronary Artery Stenoses of Diabetic Patients (PEPCAD IV)
Paclitaxel-Eluting Balloon Angioplasty and Cobalt-Chromium Stents Versus Conventional Angioplasty and Paclitaxel-Eluting Stents in the Treatment of Native Coronary Artery Stenoses of Diabetic Patients
The aim of the study is to compare the efficacy of Paclitaxel-eluting PTCA-balloon dilation (SeQuentTM Please) followed by cobalt-chromium stent (CoroflexTM Blue) deployment versus Paclitaxel-eluting stent (TaxusTM LibertéTM) deployment in the treatment of de-novo-stenoses in native coronary arteries (reference diameter:more then 2.5 mm and below 3.5 mm, length of stenosis ≥ 10 mm ≤ 20 mm) of patients with diabetes mellitus for ≥ 3 years for procedural success and preservation of vessel patency.
This study is a prospective, randomized, multi-center, two-armed phase-II pilot study conducted in Malaysia and Thailand.
128 diabetes mellitus patients shall complete the study per protocol after random assignment to either of the treatment groups on the order of 20 to 50 patients per center.
Diabetes mellitus patients with stable or selected forms of unstable angina or documented ischemia due to a de-novo stenosis in a native coronary artery will be enrolled. Vessels may not supply an entirely infarcted myocardial area.
Late lumen loss at 9 months is the primary endpoint.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Kuala Lumpur, Malaysia, 50400
- Cardiology Department, Institut Jantung Negara
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- History of diabetes mellitus of at least 3 yrs prior to enrollment. Diabetes mellitus may be treated either orally or s.c.
- Stable blood glucose level for the 6 months preceding enrollment as reflected by HbA1c concentrations measured exclusively ≤ 8 %
- Patients with stable angina pectoris (CCS class 1-3) or with unstable angina pectoris (Braunwald class 1-2, A-C) or documented ischemia or with documented silent ischemia
- Patients eligible for coronary revascularization by means of PCI
- Women of childbearing potential may not be pregnant nor have the desire to becoming pregnant during the first year following the study procedure. Hence, patients will be advised to use an adequate birth control method up to and including 6 months follow-up
- Patients who are mentally and linguistically able to understand the aim of the study and to show sufficient compliance in following the study protocol
- Patients must agree to undergo the 9 months angiographic follow-up
- Patients must agree to undergo the 3 year clinical follow-up
- De-novo native coronary artery stenosis (reference diameter: ≥2.5 mm and ≤ 3.5 mm, length of stenosis: ≥ 10 mm and ≤ 20 mm)
- Target lesion is ≥ 3 mm distant from a major side branch (> 2.0 mm in diameter) and ≥ 3 mm form a previously deployed stent of any type (including active and passive coatings, bare metal stents)
- The target lesion must be treated with a single stent only (multiple stenting shifts the patient to the intention-to-treat group)
- Single or multi-vessel coronary artery disease
Exclusion Criteria:
- Patients with acute (< 24 h) or recent (48 hours) myocardial infarction
- Patients with unstable angina pectoris (Braunwald class 3)
- Patients with severe congestive heart failure
- Patients with severe heart failure NYHA IV
- Patients with severe valvular heart disease
- Women who are pregnant or lactating
- Patients with another coronary stent implanted previously into the target vessel, drug eluting stents less than 9 months and bare metal stents or stents with passive coatings less than 3 months before the PEPCAD IV DM PCI
- Patients with bleeding diathesis in whom anticoagulation or anti-platelet medication is contraindicated
- Patients who had a cerebral stroke < 6 months prior to the procedure
- Patient participates in other clinical trials involving any investigational device or drug
- Untreated hyperthyroidism
- Patient has presence or history of severe renal failure (GFR<30ml/min) and is therefore not eligible for angiography. Patient's serum creatinine levels must be documented
- Post transplantation of any organ or immune suppressive medication
- Other disease to jeopardize follow-up (e.g., malignancy)
- Addiction to any drug or to alcohol
- Patients with any type of surgery during the week preceding the interventional procedure.
- Therapy with anticoagulants
- Poorly controlled diabetes mellitus as reflected by an HbA1c ≥ 8% during the six months prior to enrollment in PEPCAD IV DM
- Patient has a history of peptic ulcer or gastric/intestinal bleeding during the past 6 months.
- Evidence of extensive thrombosis within target vessel before the intervention
- Side branch > 2 mm in diameter originating from the lesion
- Stent within the same vessel less than 3 mm distant from target lesion
- Multi-lesion percutaneous coronary intervention within one vessel (PCI of a total of two lesions one each in a different vessels is permitted)
- Target lesion located in any type of coronary bypass (i.e., venous graft, arterial bypass) or graft/native artery connection
- Coronary artery occlusions of any type (e.g., acute or chronic)
- In-stent restenosis
- In-segment restenosis of the native vessel within 4 mm adjacent to the target lesion
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
paclitaxel eluting balloon followed by bare metal stent
|
Paclitaxel eluting balloon
bare metal stent
|
Active Comparator: 2
Paclitaxel eluting stent
|
paclitaxel eluting stent
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Late lumen loss at 9 months
Time Frame: 9 months
|
9 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Occurrence of acute (up to 48 hours), subacute (up to 30 days), and late thrombosis
Time Frame: 3 years
|
3 years
|
Procedural success
Time Frame: during procedure
|
during procedure
|
30-day MACE rate
Time Frame: 30 days
|
30 days
|
Percent in-stent stenosis at 9 months
Time Frame: 9 months
|
9 months
|
Percent in-segment stenosis at 9 months
Time Frame: 9 months
|
9 months
|
In-stent late loss index at 9 months
Time Frame: 9 months
|
9 months
|
Angiographic binary in-stent stenosis rate at 9 months
Time Frame: 9 months
|
9 months
|
In-segment late loss index at 9 months
Time Frame: 9 months
|
9 months
|
Angiographic binary in-segment stenosis rate at 9 months
Time Frame: 9 months
|
9 months
|
Acute and cumulative MACE rate at 9 months
Time Frame: 9 months
|
9 months
|
Cumulative MACE rate after 2 years
Time Frame: 2 years
|
2 years
|
Indication for premature follow-up
Time Frame: up to 9 months
|
up to 9 months
|
Type of recurrence (Mehran-Classification)
Time Frame: 9 months
|
9 months
|
Target vessel failure
Time Frame: 9 months
|
9 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Rosli M Ali, MD, Cardiology Department Institut Jantung Negara National Heart Institute
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Pathological Conditions, Anatomical
- Coronary Disease
- Constriction, Pathologic
- Coronary Stenosis
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Paclitaxel
- Albumin-Bound Paclitaxel
Other Study ID Numbers
- BBM-VS-55
- PEPCAD IV/CRI/06-03/n-c
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
Meir Medical CenterCompletedDiabetes Mellitus Type 2 | Diabetes Mellitus, Non-insulin Dependant | Diabetes Mellitus, on Oral Hypoglycemic Treatment | Adult Type Diabetes MellitusIsrael
-
Medical College of WisconsinMedical University of South CarolinaCompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type IIUnited States
-
Hanmi Pharmaceutical Company LimitedUnknownType2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
Joslin Diabetes CenterCambridge Medical Technologies, LLCCompletedType 2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Medical College of WisconsinMedical University of South Carolina; National Institute of Diabetes and Digestive...Active, not recruitingDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Medical College of WisconsinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
Clinical Trials on Paclitaxel Eluting Balloon
-
Fondazione Evidence per Attività e Ricerche Cardiovascolari...Unknown
-
Deutsches Herzzentrum MuenchenBiotronik AGCompletedAcute Coronary Syndrome | Stable Angina Pectoris | RestenosisGermany
-
University of UlmB. Braun Melsungen AGCompletedCoronary Artery Disease | Chronic Total Occlusion | Native Coronary ArteryGermany
-
Second Affiliated Hospital, School of Medicine,...West China Hospital; The Third Xiangya Hospital of Central South University; Shanghai... and other collaboratorsUnknownCoronary In-stent RestenosisChina
-
CCRF Inc., Beijing, ChinaUnknownPercutaneous Coronary InterventionChina
-
Shaare Zedek Medical CenterTerminatedDialysis Access DysfunctionIsrael
-
Catholic University of the Sacred HeartUnknown
-
Groene Hart ZiekenhuisArcher ResearchCompletedVascular Access Complication | Complication of HemodialysisBelgium, Netherlands
-
Universitätsklinikum Hamburg-EppendorfBARMER; GermanVasc; MDEpiNet Verband Deutschland e.V.Not yet recruitingOutcome, Fatal | Paclitaxel Adverse Reaction
-
Singapore General HospitalNational Medical Research Council (NMRC), SingaporeCompletedStenosis of Arteriovenous Dialysis Fistula | Arteriovenous Graft StenosisSingapore